Industry news, page-963

Storm are currently running a basket trial with their METTL3 inhibitor targeting solid tumours. Clinical validation of another m6a target would be great for us!

https://clinicaltrials.gov/ct2/show/NCT05584111

Summary of METTL3:

https://www.frontiersin.org/articles/10.3389/fonc.2022.873903/full

Coincidentally, this paper touches on FTO.

"However, due to the lack of robust methods to detect the precise modification sites of m6A in mRNA, interest in m6A research has been hindered significantly. It was not until 2011 that fat mass and obesity-associated protein (FTO) was discovered as a m6A demethylase, indicating the reversibility of the m6A modification on mRNA (5). Meanwhile, detection technology has been largely improved and has benefited the investigation of m6A modification on mRNA. Dominissini et al. and Meyer et al. independently used high-throughput sequencing to detect m6A modification at the whole transcriptome level, revealing the main distribution of m6A near stop codons, 3′ or 5′-untranslated terminal regions (UTRs), and long exons (5, 6). Due to the two critical advances, the enthusiasm and motivation of m6A research have been refueled, resulting in a flood of studies on the m6A modification on mRNA in eukaryotes."

Dominissini et al has been cited >3,200 times and he is currently testing this reversibility hypothesis, in humans, with our FICBIC FTO inhibitor!



How's this program going?